Lv1
12 积分 2024-08-21 加入
177Lu-labeled antibody-drug conjugate: a dual mechanistic treatment modality in solid tumors
10天前
已完结
Ultrasmall Folate Receptor Alpha Targeted Enzymatically Cleavable Silica Nanoparticle Drug Conjugates Augment Penetration and Therapeutic Efficacy in Models of Cancer
10天前
已完结
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer
10天前
已完结
Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers
11天前
已完结
Antibody-drug conjugates (ADCs): a novel therapy for triple-negative breast cancer (TNBC)
11天前
已完结
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
11天前
已完结
Quality-adjusted time without symptoms or toxicity analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial
11天前
已完结
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
11天前
已完结
Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States
11天前
已完结
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
11天前
已完结
皖公网安备34019202002308
